FcγR expression on NK cells influences disease severity in rheumatoid arthritis

Genes and Immunity

Volumn 5, Issue 7, 2004, Pages 521-529

  Stewart Akers, A M ^a   Cunningham, A ^a   Wasko, M C ^a   Morel, P A ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Allelic polymorphism; Fc R; NK cells; Rheumatoid arthritis

Indexed keywords

CD16 ANTIGEN; CD32 ANTIGEN; FC RECEPTOR; ISOPROTEIN;

ADULT; ALLELE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DISEASE SEVERITY; DONOR; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS;

ANTIGENS, CD; ARTHRITIS, RHEUMATOID; FEMALE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENOTYPE; HUMANS; KILLER CELLS, NATURAL; MALE; RECEPTORS, IGG; SEVERITY OF ILLNESS INDEX;

EID: 8844254698     PISSN: 14664879     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gene.6364121     Document Type: Article

References (54)

1. Winchester R, Dwyer E, Rose S. The genetic basis of rheumatoid arthritis: the shared epitope hypothesis. Rheum Dis Clin North Am 1992; 18: 761-783.
2. Jouvenne P, Chaudhary A, Buchs N et al. Possible genetic association between interleukin-1α gene polymorphism and the severity of chronic polyarthritis. Eur Cytokine Netw 1999; 10 33-36.
3. Brinkman BM, Huizinga TW, Kurban SS et al. Tumour necrosis factor alpha gene polymorphism in rheumatoid arthritis: association with susceptibility to, or severity of, disease? Br J Rheumatol 1997; 36: 516-521.
4. Moore TL, Dorner RW. Rheumatoid factors. Clin Biochem 1993; 26: 75-84.
5. Edwards JC, Cambridge G. Rheumatoid arthritis: the predictable effect of small immune complexes in which antibody is also antigen. Br J Rheum 1998; 37: 126-130.
6. Hendrich C, Kuipers JC, Kolanus W, Hammer M, Schmidt RE. Activation of CD16+ effector cells by rheumatoid factor complex. Arthritis Rheum 1991; 34: 423-431.
7. Qiu WQ, de Bruin D, Brownstein BH, Pearse R, Ravetch JV. Organization of the human and mouse low-affinity FcγR genes: evidence for duplication and recombination. Science 1990; 248: 732-735.
8. van de Winkel JGJ, Capel PJA. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today 1993; 14: 215-221.
9. Metes D, Ernst LK, Chambers WH et al. Expression of functional CD32 molecules on human NK cells is determined by an allelic polymorphism of the FcγRIIC gene. Blood 1998; 91:2369-2380.
10. Metes D, Manciulea M, Petrusca D et al. Ligand binding specificities and signal transduction pathways of FcγRIIc isoforms; the CD32 isoforms expressed by human NK cells. Eur J Immunol 1999; 29: 2842-2852.
11. Ernst LK, Metes D, Herberman RB, Morel PA. Allelic polymorphisms in the FcγRIIC gene can influence its function on normal human natural killer cells. J Mol Med 2002; 80: 248-257.
12. Salmon JE, Millard S, Schachter LA et al. Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 1996; 97: 1348-1354.
13. Sammaritano LR, Ng S, Sobel R et al. Anticardiolipin IgG subclasses: association of IgG2 with arterial and/or venous thrombosis. Arthritis Rheum 1997; 40: 1998-2006.
14. Wu J, Edberg JC, Redecha PB et al. A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997; 100: 1059-1070.
15. Yee AM, Ng SC, Sobel RE, Salmon JE. FcγRIIA polymorphism as a risk factor for invasive pneumococcal infections in systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1180-1182.
16. de Haas M, Koene HR, Kleijer M et al. A triallelic Fcγ receptor type IIIA polymorphism influences the binding of human IgG by NK cell FcγRIIIa. J Immunol 1996; 156: 2948.
17. Warmerdam PAM, van de Winkel JGJ, Gosselin EJ, Capel PJA. Molecular basis for a polymorphism of human Fcγ receptor II (CD32 . J Exp Med 1990; 172: 19-25.
18. Warmerdam PAM, Nabben NMJM, van de Graaf SAR, van de Winkel JGJ, Capel PJA. The human low-affinity immunoglobulin G Fc receptor IIC is a result of an unequal crossover event. J Biol Chem 1993; 268 7346.
19. van de Winkel JGJ, de Wit TPM, Ernst LK, Capel PJA, Ceuppens LJ. Molecular basis for a familial defect in phagocyte expression of IgG receptor I (CD64). J Immunol 1995; 156: 2896-2902.
20. Sanders LA, van de Winkel JG, Rijkers GT et al. Fc gamma receptor IIa (CD32) heterogeneity in patients with recurrent bacterial respiratory tract infections. J Infect Dis 1994; 170 854-861.
21. Bredius RGM, Derkx BHF, Fijen CAP et al. Fcγ receptor IIa (CD32) polymorphism in fulminant meningococcal septic shock in children. J Infect Dis 1994; 170: 848-853.
22. Morgan AW, Keyte VH, Babbage SJ et al. FcγRIIIA-158V and rheumatoid arthritis: a confirmation study. Rheumatology 2003; 42: 528-533.
23. Milicic A, Misra R, Agrawal S et al. The F158V polymorphism in FcγRIIIA shows disparate associations with rheumatoid arthritis in two genetically distinct populations. Ann Rheum Dis 2002; 61: 1021-1023.
24. Nieto A, Caliz R, Pascual M et al. Involvement of Fcγ receptor IIIA genotypes in susceptibility to rheumatoid arthritis. Arthritis Rheum 2000; 43: 735-739.
25. Diaz de Stahl T, Andren M, Martinsson P, Verbeek JS, Kleinau S. Expression of FcγRIII is required for development of collagen-induced arthritis. Eur J Immunol 2002; 32: 2915-2922.
26. Nabbe KC, Blom AB, Holthuysen AE et al. Coordinate expression of activating Fcγ receptors I and III and inhibiting Fcγ receptor type II in the determination of joint inflammation and cartilage destruction during immune complex-mediated arthritis. Arthritis Rheum 2003; 48: 255-265.
27. Blom AB, van Lent PL, van Vuuren H et al. Fcγ R expression on macrophages is related to severity and chronicity of synovial inflammation and cartilage destruction during experimental immune-complex-mediated arthritis (ICA). Arthritis Res 2000; 2 489-503.
28. Ji H, Ohmura K, Mahmood U et al. Arthritis critically dependent on innate immune system players. Immunity 2002; 16: 157-168.
29. Combe B, Dougados M, Goupille P et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multi-parameter prospective study. Arthritis Rheum 2001; 44: 1736-1743.
30. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46: 357-365.
31. Edwards SW, Hallett MB. Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis. Immunol Today 1997; 18: 320-324.
32. Pawlik A, Ostanek L, Brzosko I et al. FcγRIIa polymorphism in patients with rheumatoid arthritis. Clin Exp Rheumatol 2002; 20: 841-844.
33. Masuda M, Morimoto T, De Haas M et al. Increase of soluble FcγRIIIa derived from natural killer cells and macrophages in plasma from patients with rheumatoid arthritis. J Rheumatol 2003; 30: 1911-1917.
34. Metes D, Gambotto AA, Nellis J et al. Identification of the CD32/FcγRIIc-Q13/STP13 polymorphism using an allele-specific restriction enzyme digestion assay. J Immunol Meth 2001; 258: 85-95.
35. Su K, Wu J, Edberg JC, McKenzie SE, Kimberly RP. Genomic organization of classical human low-affinity Fcγ receptor genes. Genes Immun 2002; 3 (Suppl 1): S51-56.
36. Dalbeth N, Callan MF. A subset of natural killer cells is greatly expanded within inflamed joints. Arthritis Rheum 2002; 46: 1763-1772.
37. Kuipers JG, Hendrich C, Kolanus W, Hammer M, Schmidt RE. Activation of Fcγ receptor (CD16) positive natural killer cells by rheumatoid factors in rheumatoid arthritis. Immun Infect 1990; 18: 50-52.
38. McInnes IB, Liew FY. Interleukin 15: a proinflammatory role in rheumatoid arthritis synovitis. Immunol Today 1998; 19: 75-79.
39. McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med 1997; 3 189-195.
40. Tagaya Y, Bamford RN, DeFilippis AP, Waldmann TA. IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Immunity 1996; 4 329-336.
41. Salmon JE, Dalton WS. Relevance of multidrug resistance to rheumatoid arthritis: development of a new therapeutic hypothesis. J Rheumatol 1996; 44: 97-101.
42. Horwitz DA, Gray JD, Ohtsuka K, Hirokawa M, Takahashi T. The immunoregulatory effects of NK cells: the role of TGF-β and implications for autoimmunity. Immunol Today 1997; 18: 538-542.
43. Yen JH, Moore BE, Nakajima T et al. Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med 2001; 193: 1159-1167.
44. Kawanaka N, Yamamura M, Aita T et al. CD14+,CD16+ blood monocytes and joint inflammation in rheumatoid arthritis. Arthritis Rheum 2002; 46: 2578-2586.
45. Blom AB, Radstake TR, Holthuysen AE et al. Increased expression of FcγRII and III on macrophages of rheumatoid arthritis patients results in higher production of tumor necrosis factor α and matrix metalloproteinase. Arthritis Rheum 2003; 48: 1002-1014.
46. Morel PA, Feili-Hariri M, Coates PT, Thomson AW. Dendritic cells, T cell tolerance and therapy of adverse immune reactions. Clin Exp Immunol 2003; 133: 1-10.
47. Pettit AR, Thomas R. Dendritic cells: the driving force behind autoimmunity in rheumatoid arthritis? Immunol Cell Biol 1999; 77: 420-427.
48. Thomas R, Quinn C. Functional differentiation of dendritic cells in rheumatoid arthritis: role of CD86 in the synovium. J Immunol 1996; 156: 3074-3086.
49. Santiago-Schwarz F, Anand P, Liu S, Carsons SE. Dendritic cells (DCs) in rheumatoid arthritis (RA): progenitor cells and soluble factors contained in RA synovial fluid yield a subset of myeloid DCs that preferentially activate Th1 inflammatory-type responses. J Immunol 2001; 167: 1758-1768.
50. Schakel K, Kannagi R, Kniep B et al. 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. Immunity 2002; 17: 289-301.
51. Arnett FC, Edworthy SM, Bloch DA. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324.
52. Morel PA, Chang HJ, Wilson J et al. Severe systemic sclerosis with anti-topoisomerase antibodies is associated with an HLA-DRw11 allele. Hum Immunol 1994; 40: 101-110.
53. Koene HR, Kleijer M, Algra J et al. FcγRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcγRIIIa, independently of the FcγRIIIa-48L/R/H phenotype. Blood 1997; 90: 1109-1114.
54. 131 ligand-binding polymorphism using an allele-specific restriction enzyme digestion (ASRED). J Immunol Meth 1996; 199: 55-59.